Mt. Sinai, Berg Ink Omics Deal Directed at Cancer, CNS, Endocrine Disorders | GenomeWeb

NEW YORK (GenomeWeb News) – The Icahn School of Medicine at Mt. Sinai and biopharmaceutical firm Berg today announced a five-year partnership aimed at cancer, as well as central nervous system and endocrine disorders.

The agreement will take a multi-omics and big data analytical approach to gain insight into the three disease areas in order to potentially develop therapeutics and diagnostic tools, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.